UGT1A1 sirna

UGT1A1 siRNA (Human)

Cat. Num. AAA827885

• Gene Names: UGT1A1; GNT1; UGT1; UDPGT; UGT1A; HUG-BR1; BILIQTL1; UDPGT 1-1
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: UGT1A1; UGT1A1 siRNA (Human); GNT1; UGT1; UDP-glucuronosyltransferase 1-1; UDPGT 1-1; UGT1*1; UGT1-01; UGT1.1; Bilirubin-specific UDPGT isozyme 1; hUG-BR1; UDP-glucuronosyltransferase 1-A; UGT-1A; UGT1A; UDP-glucuronosyltransferase 1A1; UGT1A1 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: UGT1A1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 444

• Applicable Applications for UGT1A1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human UGT1A1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for UGT1A1 sirna

siRNA to inhibit UGT1A1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 8850236
• NCBI GeneID: 54658
• NCBI Accession #: NP_000454.1
• NCBI GenBank Nucleotide #: NM_000463.2
• UniProt Accession #: P22309; A6NJC3; B8K286
• Molecular Weight: 49,368 Da
• NCBI Official Full Name: UDP-glucuronosyltransferase 1-1
• NCBI Official Synonym Full Names: UDP glucuronosyltransferase 1 family, polypeptide A1
• NCBI Official Symbol: UGT1A1
• NCBI Official Synonym Symbols: GNT1; UGT1; UDPGT; UGT1A; HUG-BR1; BILIQTL1; UDPGT 1-1
• NCBI Protein Information: UDP-glucuronosyltransferase 1-1
• UniProt Protein Name: UDP-glucuronosyltransferase 1-1
• Protein Family: UDP-glucuronosyltransferase
• UniProt Gene Name: UGT1A1
• UniProt Synonym Gene Names: GNT1; UGT1; UDPGT 1-1; UGT1*1; UGT1-01; UGT1.1; hUG-BR1; UGT-1A; UGT1A
• UniProt Entry Name: UD11_HUMAN

NCBI Description

This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The preferred substrate of this enzyme is bilirubin, although it also has moderate activity with simple phenols, flavones, and C18 steroids. Mutations in this gene result in Crigler-Najjar syndromes types I and II and in Gilbert syndrome. [provided by RefSeq, Jul 2008]

Uniprot Description

UGT1A1: UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX- alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4- methylumbelliferone, 1-naphthol, paranitrophenol, scopoletin, and umbelliferone. Part a large chaperone multiprotein complex comprising DNAJB11, HSP90B1, HSPA5, HYOU, PDIA2, PDIA4, PDIA6, PPIB, SDF2L1, UGT1A1 and very small amounts of ERP29, but not, or at very low levels, CALR nor CANX. Expressed in liver. Not expressed in skin or kidney. Belongs to the UDP-glycosyltransferase family. 1 isoforms of the human protein are produced by alternative splicing.

Protein type: Lipid Metabolism - androgen and estrogen; Membrane protein, integral; Cofactor and Vitamin Metabolism - porphyrin and chlorophyll; Xenobiotic Metabolism - drug metabolism - cytochrome P450; Carbohydrate Metabolism - starch and sucrose; Carbohydrate Metabolism - pentose and glucuronate interconversions; Xenobiotic Metabolism - drug metabolism - other enzymes; Carbohydrate Metabolism - ascorbate and aldarate; Cofactor and Vitamin Metabolism - retinol; Transferase; EC 2.4.1.17; Xenobiotic Metabolism - metabolism by cytochrome P450

Chromosomal Location of Human Ortholog: 2q37

Cellular Component: endoplasmic reticulum membrane; endoplasmic reticulum; integral to plasma membrane

Molecular Function: enzyme inhibitor activity; retinoic acid binding; enzyme binding; protein homodimerization activity; glucuronosyltransferase activity; protein heterodimerization activity; steroid binding

Biological Process: response to drug; steroid metabolic process; estrogen metabolic process; organ regeneration; negative regulation of steroid metabolic process; response to lipopolysaccharide; negative regulation of fatty acid metabolic process; liver development; cellular response to hormone stimulus; response to starvation; negative regulation of transferase activity; flavonoid biosynthetic process; bilirubin conjugation; heme catabolic process; xenobiotic metabolic process; digestion; negative regulation of catalytic activity; porphyrin metabolic process; flavone metabolic process; acute-phase response; retinoic acid metabolic process; heterocycle metabolic process; drug metabolic process; response to nutrient

Disease: Gilbert Syndrome; Crigler-najjar Syndrome, Type I; Bilirubin, Serum Level Of, Quantitative Trait Locus 1; Crigler-najjar Syndrome, Type Ii; Hyperbilirubinemia, Transient Familial Neonatal